本文選題：肺表面活性物質(zhì) + 肺炎支原體��； 參考：《南京醫(yī)科大學(xué)學(xué)報(自然科學(xué)版)》2017年06期

【摘要】：目的:探討肺表面活性物質(zhì)相關(guān)蛋白A(surfactant protein-A,SP-A)在肺炎支原體肺炎(Mycoplasma pneumoniae pneumonia,MPP)中的作用及臨床意義。方法:收集2014年1月1日—2015年12月31日在南京醫(yī)科大學(xué)附屬兒童醫(yī)院住院的肺炎患兒共51例:其中MPP患兒41例,分別為MPP組15例,MPP伴肺不張組26例,同時設(shè)立同期入院非支原體感染的普通肺炎10例為對照組,采用ELISA法檢測各組患兒血清和肺泡灌洗液(bronchoalveolar lavage fluid,BALF)中SP-A含量,逆轉(zhuǎn)錄聚合酶鏈反應(yīng)方法(RT-PCR)檢測血清SP-A m RNA相對表達情況。結(jié)果:(1)MPP組、MPP伴肺不張組血清、BALF中SP-A蛋白水平均低于對照組,差異均有統(tǒng)計學(xué)意義(P0.05),但MPP組、MPP伴肺不張組之間差異無統(tǒng)計學(xué)意義(P0.05)。(2)MPP組及MPP伴肺不張組血清SP-A含量及m RNA水平與BALF中SP-A蛋白含量均呈正相關(guān)(r=0.42,P=0.01;r=0.41,P=0.04)。(3)MPP伴肺不張組血清、BALF中SP-A含量及血清SP-A m RNA水平與肺復(fù)張時間無明顯相關(guān)性(P值均0.05)。結(jié)論:MPP患兒血清、BALF中SP-A蛋白含量明顯下降,MPP中可能存在肺泡Ⅱ型細胞損傷,SP-A的替代治療或促進SP-A生成的治療對MPP的恢復(fù)將有一定意義。
[Abstract]:Objective: to investigate the role of pulmonary surfactant associated protein (A(surfactant protein-An SP-A) in Mycoplasma pneumoniae pneumonia (Mycoplasma pneumoniae) and its clinical significance. Methods: from January 1, 2014 to December 31, 2015, 51 children with pneumonia were enrolled in the affiliated Children's Hospital of Nanjing Medical University, including 41 patients with MPP, including 15 patients with MPP and 26 patients with atelectasis. At the same time, 10 cases of common pneumonia with non-mycoplasma infection were used as the control group. The levels of SP-A in serum and bronchoalveolar lavage fluidform (BALF) of children in each group were detected by ELISA method. Reverse transcriptase polymerase chain reaction (RT PCR) was used to detect the relative expression of SP-A m RNA in serum. Results the level of SP-A protein in serum of MPP group with atelectasis was lower than that of control group. The difference was statistically significant (P 0.05), but there was no significant difference between MPP group and MPP with atelectasis group. There was a positive correlation between the level of serum SP-A and m RNA and the content of SP-A protein in BALF. There was no significant correlation between the level of SP-A and the level of serum SP-A m RNA and lung extension time (P = 0.05). Conclusion the level of SP-A protein in the serum of children with BALF decreased significantly. There may be replacement therapy of SP-A for alveolar type 鈪，

本文編號：1870923